Company / Cash & Equivalents
Boston Scientific Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.0B
FY2025
5-year range
$414.0M / $2.0B
FY2021-FY2025
Trend
+374.6%
vs FY2024
Sector context
#21 of 148
Health Care
What the data says
Cash & Equivalents changed +375% YoY in FY2025, a notable deviation from the 9-year average annual change of +110%.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +55.4%. Top quartile in the Health Care sector.
Improved from $865M to $2.0B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +28.4%
- 5-Year CAGR
- +55.4%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 148This company $2.0B Sector average $1.2B
▼
+67.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +55.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 374.6% year-over-year.
- Ranks #21 out of 148 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +374.6% |
| FY2024 | $414.0M | -52.1% |
| FY2023 | $865.0M | -6.8% |
| FY2022 | $928.0M | -46.5% |
| FY2021 | $1.7B | +699.1% |
| FY2020 | $217.0M | +0.0% |
| FY2019 | $217.0M | +48.6% |
| FY2018 | $146.0M | -22.3% |
| FY2017 | $188.0M | -4.1% |
| FY2016 | $196.0M | -38.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026